Drugs / MK0952
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00362024 | Nov 2006 → Nov 2007 | Alzheimer disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK0952 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00362024 ↗ |
| Action | Inhibit | “MK0952 is a phosphodiesterase type IV (PDE4) inhibitor” NCT00362024 ↗ |